Media coverage about Crispr Therapeutics (NASDAQ:CRSP) has been trending somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Crispr Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.7141437842985 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- CRISPR Therapeutics AG (NASDAQ:CRSP) – Hot Stock Analysis – Nasdaq Journal (nasdaqjournal.com)
- Hot Stock’s Trend Recap – CRISPR Therapeutics AG (NASDAQ: CRSP) – Alpha Beta Stock (alphabetastock.com)
- Magnetizing Stocks: CRISPR Therapeutics AG, (NASDAQ: CRSP), Morgan Stanley, (NYSE: MS); – TNN (tradingnewsnow.com)
- CRISPR Therapeutics AG (NASDAQ:CRSP) – Market Cap Analysis – Nasdaq Journal (nasdaqjournal.com)
- 3 Reasons CRISPR Stocks Could Keep Soaring – Madison.com (host.madison.com)
CRSP has been the topic of a number of recent research reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $53.70 price objective (down from $67.00) on shares of Crispr Therapeutics in a research note on Friday, March 9th. BidaskClub upgraded shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. Finally, ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $53.53.
In related news, insider Tyler Dylan-Hyde sold 15,000 shares of the stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $20.55, for a total transaction of $308,250.00. Following the completion of the sale, the insider now owns 115,204 shares of the company’s stock, valued at $2,367,442.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Aktiengesellschaft Bayer bought 527,472 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The shares were purchased at an average cost of $22.75 per share, with a total value of $11,999,988.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 283,850 shares of company stock worth $7,261,865. Insiders own 39.98% of the company’s stock.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.